Bictegravir/emtricitabine/tenofovir alafenamide

Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023

Retrieved on: 
Monday, October 16, 2023
Health, Hospitals, Research, Pharmaceutical, Science, Biotechnology, Partnership, PWH, Lenacapavir, XVII International AIDS Conference, 2008, Doctor of Philosophy, HIV Prevention Trials Network, Faculty, Drug development, Anxiety, Abstract, Drug resistance, European, EACS, Success, MD, Elton John AIDS Foundation, Risk, Chicano Art: Resistance and Affirmation, HIV-1, Death, Safety, HIV, EECA, CAPELLA, ART, DAI, Patient, CEST, Mental health, Education, Insomnia, Person, Mental, RSP, Tablet, Gilead Sciences, AIDS, Depression, History, Boxed warning, Elton, Conference, Monogram, Pharmaceutical industry, Medical device, Vaccine, Empowerment, Bictegravir/emtricitabine/tenofovir alafenamide

As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs.

Key Points: 
  • As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs.
  • Additional lenacapavir data presented at EACS 2023 will provide insight into the therapy’s resistance profile.
  • The mental health outcomes reported by participants in BICSTaR over a two-year period will also be presented at EACS 2023.
  • Mental health impairments can further increase the risk of negative health outcomes at every stage of the HIV care continuum.

Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, FDA, AIDS, Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Science, COVID-19, Clinical Trials, XBF, Abstract, Gilead Sciences, Omicron, Senior, HIV, Obeldesivir, Virology, SARS-CoV-2, Safety, Pre-exposure prophylaxis, Lenacapavir, HIV capsid inhibition, Tablet, Drug resistance, MD, Patient, Boxed warning, Liver, CAPELLA, Pharmaceutical industry, Bictegravir/emtricitabine/tenofovir alafenamide, Remdesivir

These latest data demonstrate the company’s ongoing efforts to address the unmet medical needs of people and communities affected by HIV and COVID-19.

Key Points: 
  • These latest data demonstrate the company’s ongoing efforts to address the unmet medical needs of people and communities affected by HIV and COVID-19.
  • Gilead will be presenting 16 abstracts, including real-world evidence, as the company continues to pursue the next wave of scientific discovery in virology.
  • “At IDWeek 2023, we look forward to sharing our latest data with the broader community and discussing potential implications for the treatment of COVID-19 among some of the most vulnerable populations.
  • At IDWeek 2023, Gilead will present data that reinforces the ongoing role Veklury® (remdesivir) plays as the antiviral standard of care for the treatment of hospitalized patients with COVID-19.

Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023

Retrieved on: 
Wednesday, July 19, 2023
AIDS, Health, Infectious Diseases, Hospitals, Pharmaceutical, Biotechnology, Science, Emtricitabine, Maintenance, Gilead Sciences, Elton, Bictegravir/emtricitabine/tenofovir alafenamide, International, Public affairs, Senior, HIV, Health equity, AEST, Woman, Lenacapavir, Research, Doctor of Philosophy, Tablet, Elton John AIDS Foundation, DTG, HIV/AIDS denialism, MD, The Fire Within, IAS, Crisis communication, Conference, CAPELLA, Pharmaceutical industry

As the leader in HIV innovation, Gilead will provide updates on its signature initiatives and key collaborations while sharing new scientific data from its research and development programs.

Key Points: 
  • As the leader in HIV innovation, Gilead will provide updates on its signature initiatives and key collaborations while sharing new scientific data from its research and development programs.
  • Gilead is committed to continuous scientific discovery to meet the evolving needs of people affected by HIV.
  • At IAS 2023, Gilead will share new findings on HIV treatment and prevention strategies, as well as the latest updates from the company’s continued pursuit of an HIV cure.
  • Gilead scientists will also contribute to three IAS-hosted satellite sessions to further advance scientific dialogue on key issues including:

Global HIV Treatment Market Analysis Report 2023: A $25+ Billion Market by 2030 - Focus on Combination Therapies Gaining Momentum - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 29, 2023
AIDS, Pharmaceutical, Health, Hetero Drugs, Telehealth, Gilead Sciences, Drug development, EU, The, Prevalence, HIV, Islatravir, Sun Pharma, MPP, Public, Sustainable Development Goal 3, COVID-19, Collaboration, Health equity, Quality of life, Hope, ART, Research, ViiV Healthcare, Cipla, Medicines Patent Pool, Drug resistance, Non-governmental organization, Patient, Risk, Mylan, Hook effect, Aurobindo Pharma, Sustainable Development Goals, Artificial intelligence, Growth, Merck, FDA, UNAIDS, Pharmaceutical industry, Vaccine, Medical device, Bictegravir/emtricitabine/tenofovir alafenamide, Tenofovir alafenamide, Capsid, Dolutegravir/lamivudine, Lenacapavir, Dolutegravir/rilpivirine, Generic

The "Global HIV Treatment Market: Analysis By Product, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global HIV Treatment Market: Analysis By Product, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global HIV treatment market in 2022 stood at US$22.38 billion, and is likely to reach US$25.49 billion by 2030.
  • The global HIV treatment market is projected to grow at a CAGR of 1.42% during the forecast period of 2023-2030.
  • These ongoing efforts are instrumental in shaping the future of the global HIV treatment market.

Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection

Retrieved on: 
Wednesday, February 22, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, AIDS, Health, Pharmaceutical, General Health, Science, MSD, PWH, Infection, Randomness, Management of HIV/AIDS, HIV, Conference on Retroviruses and Opportunistic Infections, HIV-1, NYSE, Fungal infection, Islatravir, Vargo, Subtypes of HIV, Bictegravir/emtricitabine/tenofovir alafenamide, Merck & Co., Conference, DOR, MRK, CROI, Pharmaceutical industry, Dietary supplement, Silviculture, Merck, R, Safety

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has opened enrollment in its new Phase 3 clinical program with investigational once-daily islatravir 0.25 mg in combination with doravirine 100 mg (DOR/ISL) for the treatment of HIV-1 infection.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has opened enrollment in its new Phase 3 clinical program with investigational once-daily islatravir 0.25 mg in combination with doravirine 100 mg (DOR/ISL) for the treatment of HIV-1 infection.
  • Select Merck abstracts for islatravir at the Conference on Retroviruses and Opportunistic Infections (CROI) 2023 include:
    Switch to DOR/ISL (100/0.75MG) QD From B/F/TAF: Week 48 Results From a Phase 3 Trial.
  • For more than 35 years, Merck has been committed to scientific research and discovery (R&D) in HIV.
  • We remain committed to working hand-in-hand with our partners in the global HIV community to address the complex challenges that impede progress toward ending the epidemic.

Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023

Retrieved on: 
Tuesday, February 14, 2023
Biotechnology, AIDS, Health, General Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Hospitals, Science, COVID-19, Lenacapavir, Viral, International AIDS Society, CROI, Woman, Fungal infection, Immunotherapy, Abstract, Pre-exposure prophylaxis, Safety, Incidence, Patient, Boxed warning, HBV, HIV, Food, Gilead Sciences, Senior, Virology, Coinfection, International, DTG, TLR9, Hook effect, Conference on Retroviruses and Opportunistic Infections, Vesatolimod, Emtricitabine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, Tablet, MD, Pharmaceutical industry, Vaccine, Remdesivir, Bictegravir/emtricitabine/tenofovir alafenamide

At CROI 2023, Gilead will share new findings on HIV treatment and prevention strategies, as well as the latest updates from the company’s continued pursuit of an HIV cure.

Key Points: 
  • At CROI 2023, Gilead will share new findings on HIV treatment and prevention strategies, as well as the latest updates from the company’s continued pursuit of an HIV cure.
  • Additionally, Gilead will present data from a pre-clinical in vivo assessment of a single subcutaneous administration of lenacapavir for pre-exposure prophylaxis (PrEP).
  • Gilead will present data that reinforce the critical role Veklury® (remdesivir) plays as the antiviral standard of care for the treatment of hospitalized patients with COVID-19.
  • Additionally, Gilead will present a new in vitro analysis that evaluates the antiviral activity of Veklury against common variants of concern, and data assessing the resistance profile of Veklury and other antiviral compounds.

European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations

Retrieved on: 
Tuesday, November 29, 2022
Children, Biotechnology, AIDS, Other Health, Health, Pharmaceutical, Infectious Diseases, Hospitals, Consumer, Teens, Clinical Trials, Gilead Sciences, Tablet, Doctor of Philosophy, Disulfiram-like drug, European Medicines Agency, Science, Union, Tenofovir disoproxil, Food, Risk, Emtricitabine, Physician, Week, Patient, Drug, Pre-exposure prophylaxis, Education, Royal commission, HIV-1, European Commission, Medicine, Death, MD, European, STR, Medication package insert, AIDS, Cancer, Brain Tumor Funders' Collaborative, Health, Research, Ageing, HIV, EC, Safety, Pharmaceutical industry, Vaccine, Bictegravir/emtricitabine/tenofovir alafenamide, EU

The European Marketing Authorization is the first pediatric approval for Biktarvy in the European Union (EU) and applies to all 27 member states of the EU, as well as Norway, Iceland and Liechtenstein.

Key Points: 
  • The European Marketing Authorization is the first pediatric approval for Biktarvy in the European Union (EU) and applies to all 27 member states of the EU, as well as Norway, Iceland and Liechtenstein.
  • Additional therapy choices help to ensure children can access care and expand their HIV treatment options, which helps advance the collective efforts to overcome the HIV epidemic.
  • Through the Gilead Global Pediatric Center of Excellence, we are committed to applying our decades of antiviral expertise to drive innovation in pediatric HIV research.
  • In 2021, an estimated 800,000 children under the age of 19 living with HIV were still not receiving HIV treatment.

Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities

Retrieved on: 
Monday, October 24, 2022
Health, Infectious Diseases, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Prevalence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Diarrhea, HIV, International Congress on Tuberculosis, Gilead Sciences, AIDS, Sex, Food, Pharmacotherapy, MD, Doctor of Philosophy, Science, Safety, Clinical trial, Nasdaq, Boxed warning, AE, FDA, COVID-19, Tablet, Pharmaceutical industry, Bictegravir/emtricitabine/tenofovir alafenamide

Treatment discontinuations (14% overall) were low, and few people (7%) discontinued Biktarvy as a result of drug-related AEs (DRAEs).

Key Points: 
  • Treatment discontinuations (14% overall) were low, and few people (7%) discontinued Biktarvy as a result of drug-related AEs (DRAEs).
  • These data reinforce the safety and durability of Biktarvy for people with HIV with a high level of comorbidities.
  • The BICSTaR study reinforces the real-world effectiveness of Biktarvy across populations with a range of comorbidities and the findings are consistent with evidence from randomized clinical trials of Biktarvy treatment.
  • Biktarvy, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022

Retrieved on: 
Tuesday, October 18, 2022
Health, Infectious Diseases, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, European Medicines Agency, Union, Kidney, Infection, PRT, Assessment of kidney function, HIV/AIDS, Dofetilide, Person, Fanconi syndrome, Emtricitabine, TAF, Patient, Rifampicin, HIV, International Congress on Tuberculosis, European Market Infrastructure Regulation, RNA, CAPELLA, Research, Gilead Sciences, HIV-1, History, AIDS, TDF, Hepatitis B, Sex, Pharmacotherapy, Creatinine, Drug interaction, Drug, Disulfiram-like drug, MD, Doctor of Philosophy, Science, Contraindication, Boxed warning, Safety, FTC, 2021 Essex County Council election, Product, HBV, Degenerative disease, Week, Nasdaq, Lenacapavir, Kidney failure, Medication package insert, Tablet, Postmarketing surveillance, Pharmaceutical industry, Vaccine, Bictegravir/emtricitabine/tenofovir alafenamide, EU

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the companys upcoming new data from its HIV research and development programs to be presented at the 30th International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2022) in Glasgow, Scotland and virtually from October 23-26, 2022.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced the companys upcoming new data from its HIV research and development programs to be presented at the 30th International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2022) in Glasgow, Scotland and virtually from October 23-26, 2022.
  • The data presented at HIV Glasgow reflect the latest progress in our research and development programs and underscore Gileads commitment to driving transformational innovation in HIV research.
  • Biktarvy, Sunlenca, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter ( @Gilead Sciences ) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic

Retrieved on: 
Thursday, July 21, 2022
Science, Biotechnology, Research, Pharmaceutical, AIDS, Health, Hospitals, Clinical Trials, PRT, Emtricitabine, Creatinine, Lenacapavir, Kidney failure, TAF, Postmarketing surveillance, Doctor of Philosophy, 2021 Essex County Council election, Tablet, International AIDS Society, Research, HIV-1, Biomarker, History, Partnership, Boxed warning, Solution, DTG, Vesatolimod, Drug interaction, Randomized controlled trial, Drug, Degenerative disease, Nasdaq, FTC, TDF, Contraindication, Safety, COVID-19, Conference, Kidney, Hepatitis B, Dofetilide, AIDS, Senior, MD, CAPELLA, Gilead Sciences, COMPASS, Pharmacokinetics, Patient, Science, Assessment of kidney function, Fanconi syndrome, International, Subtypes of HIV, Rifampicin, HIV, ART, Public affairs, HBV, Pharmaceutical industry, Dietary supplement, Vaccine, Bictegravir/emtricitabine/tenofovir alafenamide

The convergence of the COVID-19 pandemic and HIV epidemic has further highlighted how inequities result in adverse health outcomes.

Key Points: 
  • The convergence of the COVID-19 pandemic and HIV epidemic has further highlighted how inequities result in adverse health outcomes.
  • At AIDS 2022, Gilead will convene a diverse, global panel Working Together to End the Epidemic: Guided by the Voices on the Ground to discuss community perspectives and Gileads ongoing efforts to change the future of the HIV epidemic through catalytic collaboration.
  • Gilead is driving scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world, with the goal of ending the HIV epidemic for everyone, everywhere.
  • During AIDS 2022, Gilead will share new findings on HIV treatment and prevention strategies, as well as the latest updates from the companys continued pursuit of an HIV cure.